echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > Sword refers to specific lung cancer!

    Sword refers to specific lung cancer!

    • Last Update: 2021-09-13
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    The latest announcement by the Center for Drug Evaluation (CDE) of the National Medical Products Administration of China shows that Novartis's classic dual-target combination therapy-dabrafenib/trametinib is planned to be included in the priority review and is suitable for the treatment of BRAF V600 mutation-positive patients.


    It is suitable for the treatment of patients with advanced non-small cell lung cancer with BRAF V600 mutation positive

    Screenshot source: CDE official website

    Dabrafenib and trametinib target different kinases in the serine/threonine kinase family in the RAS/RAF/MEK/ERK pathway, BRAF and MEK1/2 , respectively.


    Respectively target different kinases in the serine/threonine kinase family in the RAS/RAF/MEK/ERK pathway-BRAF and MEK1/2

    It is worth mentioning that tadalafil Nepal and the United States original song by GlaxoSmithKline (GSK) has imatinib, codenamed respectively GSK2118436 and GSK1120212.


    Novartis acquired the latter's oncology business for a total of $16 billion in cash consideration

    In China, the dabrafenib/trametinib combination therapy was first approved for marketing in China in December 2019 to treat BRAF V600 mutation-positive unresectable or metastatic melanoma


    The dabrafenib/trametinib combination therapy was first approved for marketing in China in December 2019.


    Because these mutant tumors are more malignant and respond poorly to standard chemotherapy, they are more likely to lead to poor prognosis


    Screenshot source: CDE official website

    As early as June 2017, dabrafenib/trametinib combination therapy has been approved by the U.


    For the treatment of non-small cell lung cancer patients whose tumors carry BRAF V600E mutations, the overall response rate (ORR) reached 61%, and the ORR reached 63%

    According to a press release issued by Novartis earlier, this is an important milestone in the field of lung cancer


    This is an important milestone in the field of lung cancer


    Reference materials:

    Reference materials:

    [1] Center for Drug Evaluation (CDE) of China National Medical Products Administration.


    [2] Tefila (dalafenib) and Meginine (trametinib) were approved to be listed in China.


    [3] Dual-target therapy for double happiness—Tefir® and Maijining® were approved for adjuvant therapy indications.


    [4] Novartis AG (NVS) Combination Targeted Therapy Tafinlar + Mekinist Receives FDA Approval For BRAF V600E Mutant Metastatic Non-Small Cell Lung Cancer (NSCLC).
    Retrieved Jun 22.
    2017.
    from https:// -releases/novartis-combination-targeted-therapy-tafinlar-mekinist-receives-fda-approval-braf-v600e-mutant-metastatic-non-small-cell-lung-cancer-nsclc#:~:text=Basel%2C% 20June%2022%2C%202017%20-%20Novartis%20today%20announced,%28NSCLC%29%20whose%20tumors%20express%20the%20BRAF%20V600E%20mutation.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.